AzTrials
AzTrials

SciaticaNCT07377357

Immediate and 1-week Efficacy of a Single Session of Sciatic Nerve Electrical Stimulation in the Management of Low-back Related Leg Pain

A study testing Percutaneous Electrical Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation and Real Dry Needling (without Percutaneous Electrical Nerve Stimulation) in people with Sciatica, run by Universidad Complutense de Madrid at 1 site in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This clinical study focuses on people who experience long-term low-back related leg pain (commonly called sciatica). This type of pain is often associated with nerve irritation or compression in the lower spine and can cause symptoms like shooting or burning pain, tingling, numbness, or weakness in the leg. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Sciatica
What is being tested?
Percutaneous Electrical Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation and Real Dry Needling (without Percutaneous Electrical Nerve Stimulation)
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
88 participants
Where
1 siteSpain
Study dates
13 May 2026to Nov 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Neuropathic-like LBRLP (sciatica).
  • S-LANSS score ≥ 12 points.
  • LBRLP lasting more than 6 months.
  • Age between 18 and 70 years.
  • LBRLP in the past 4 weeks has been severe enough to limit usual activities or change daily routines for more than 1 day.
  • At least one period of 6 months to 1 year during which the participant did not go a full month without LBRLP.
  • LBRLP intensity of at least 3/10 on the NPRS.
  • Ability to provide informed consent.

Who cannot join

  • Acute injury or recent major trauma history.
  • Relevant painful conditions of the hip joint or pelvic/sacroiliac region.
  • Symptoms compatible with cauda equina syndrome (loss of bladder/bowel control, sexual dysfunction, paralysis of lower limbs, etc.).
  • Previous surgery on the spine, pelvis or hip.
  • Prior treatment with anesthetic or anti-inflammatory blocks or with radiofrequency (facet, sacroiliac, radicular, epidural, etc.) in the past two years.
  • Any neurological or systemic disease that could limit participation in the study.
  • Inability to communicate in Spanish or understand study instructions and content.
  • General contraindications for invasive physiotherapy and electrotherapy techniques.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Spain1 site, 1 recruiting
  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, 28041

    Gabriel R Rabanal-Rodríguez, 0034 91 394 15 24, grabanal@ucm.es

    Recruiting

Other trials in Spain

About this study

This clinical study focuses on people who experience long-term low-back related leg pain (commonly called sciatica). This type of pain is often associated with nerve irritation or compression in the lower spine and can cause symptoms like shooting or burning pain, tingling, numbness, or weakness in the leg. Many patients continue to suffer from this problem for months or years, and available treatments (including painkillers, anti-inflammatory drugs, or even surgery) do not always provide lasting relief. Because of this, there is a strong need to explore safe, non-drug, non-surgical therapies. The purpose of this study is to test the immediate and short-term efficacy and safety of a single session of a treatment called Percutaneous Electrical Nerve Stimulation (PENS) when applied near the sciatic nerve, the large nerve that runs from the lower back through the buttock and down the leg. PENS uses very thin sterile needles inserted under ultrasound guidance next to the nerve. A gentle electrical current is then applied for about 30 minutes to stimulate the nerve in a controlled way. This may help calm down nerve sensitivity, reduce inflammation, and decrease pain. The investigators will compare PENS with three other options: Transcutaneous Electrical Nerve Stimulation (TENS): A commonly used therapy where mild electrical stimulation is applied through adhesive patches placed on the skin; Dry needling without electrical current: Thin needles are inserted under ultrasound guidance but no current is applied; and placebo treatment: A simulated version of the therapy with no active current, designed to look and feel similar so that participants do not know which treatment they are receiving. The study is designed as a randomized, controlled, double-blind trial, which means that participants are assigned to one of the four groups by chance (like flipping a coin), and neither the patients nor the therapists who collect the measurements will know which treatment has been given. This design ensures fairness and reliability of the results. The investigators will measure: Back and leg pain levels, using a simple 0-10 scale; Disability, meaning how much the pain limits daily activities, measured with a well-known questionnaire; Quality of life, both physical and mental health aspects; Nerve-related pain features, like burning or electric-like sensations; Flexibility and movement, through the Straight Leg Raise test; Sensitivity to pressure and nerve stiffness, using ultrasound elastography, which is a safe imaging technique; and patients' global impression of improvement and any side effects. Assessments will take place before and immediately after the treatment session and after 1 week, allowing the investigators to see both the immediate and short-term effects. Safety considerations: Previous research shows that PENS and similar techniques are generally very safe. The most common side effects are mild and short-lasting, including temporary soreness, heaviness in the leg, or a small bruise. Serious complications are extremely rare. To minimize risks, all procedures will be carried out by experienced physiotherapists, using real-time ultrasound to guide needle placement and ensure accuracy. Only sterile, single-use needles are employed. By comparing PENS, TENS, dry needling, and placebo, this study seeks to determine whether a single session of PENS provides superior benefits in reducing pain, improving function, and enhancing quality of life for patients with sciatica-type low back pain. If successful, this treatment could become a valuable alternative to drugs or surgery, offering patients a safe and effective therapy to better manage their condition and regain daily function.

Conditions
Sciatica
Being tested
Percutaneous Electrical Nerve Stimulation, Placebo Transcutaneous Electrical Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation, Placebo Percutaneous Electrical Nerve Stimulation, Real Dry Needling (without Percutaneous Electrical Nerve Stimulation)
Medical subject headings
Sciatica

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Percutaneous Electrical Nerve StimulationProcedure or surgery

    Also called PENS

    Participants will receive real ultrasound-guided dry needle insertion (0.30 mm × 60 mm and 0.30 mm ×50 mm) to the perineural region adjacent to the sciatic nerve at both the subgluteal fold and the posterior thigh (junction between the middle and distal thirds). Electrical stimulation will be applied using the Endomed 484® electrotherapy unit (PRIM Physio, Madrid, Spain) in continuous biphasic mode at low frequency (2 Hz), 250 μs pulse width for 30 minutes. Intensity will be adjusted to elicit a visible, mild muscle contraction.

  • Placebo Transcutaneous Electrical Nerve StimulationProcedure or surgery

    Also called Placebo TENS

    Adhesive electrodes will be placed near the intervention site (sciatic nerve between the subgluteal fold and the distal third of the thigh) but connected to a disabled channel to simulate placebo TENS.

  • Transcutaneous Electrical Nerve StimulationProcedure or surgery

    Also called TENS

    Participants will receive real superficial electrical stimulation via adhesive electrodes connected to the Endomed 484® unit, configured for TENS (non-invasive). Parameters will include continuous biphasic current, 2 Hz, 250 μs, 30 min, producing a clear sensory perception and mild muscle contraction.

  • Placebo Percutaneous Electrical Nerve StimulationProcedure or surgery

    Also called Placebo PENS

    A sham ultrasound-guided dry needling procedure will be performed using Streitberger placebo needles, which contact the skin superficially without penetration. Cables for PENS will be placed on the skin but connected to a disabled channel to simulate placebo PENS.

  • Real Dry Needling (without Percutaneous Electrical Nerve Stimulation)Procedure or surgery

    Also called Real Dry Needling (without PENS)

    Participants will receive real ultrasound-guided dry needling but without electrical stimulation. The needles will remain in place for 30 minutes, with the PENS channel disabled to act as placebo.

Study groups in NCT07377357
Study groupRoleWhat they receive
Real PENS + Placebo TENSExperimentalParticipants will receive real ultrasound-guided dry needle insertion (0.30 mm × 60 mm and 0.30 mm ×50 mm) to the perineural region adjacent to the sciatic nerve at both the subgluteal fold and the posterior thigh (junction between the middle and distal thirds). Electrical stimulation will be applied using the Endomed 484® electrotherapy unit (PRIM Physio, Madrid, Spain) in continuous biphasic mode at low frequency (2 Hz), 250 μs pulse width for 30 minutes. Intensity will be adjusted to elicit a visible, mild muscle contraction. Simultaneously, adhesive electrodes will be placed near the intervention site but connected to a disabled channel to simulate placebo TENS.
Receives: Procedure: Percutaneous Electrical Nerve Stimulation; Procedure: Placebo Transcutaneous Electrical Nerve Stimulation
Real TENS + Placebo PENSActive comparatorParticipants will receive real superficial electrical stimulation via adhesive electrodes connected to the Endomed 484® unit, configured for TENS (non-invasive). Parameters will match those from Group 1 (continuous biphasic current, 2 Hz, 250 μs, 30 min), producing a clear sensory perception and mild muscle contraction. Simultaneously, a sham ultrasound-guided dry needling procedure will be performed using Streitberger placebo needles, which contact the skin superficially without penetration. Cables for PENS will be placed on the skin but connected to a disabled channel to simulate placebo PENS.
Receives: Procedure: Transcutaneous Electrical Nerve Stimulation; Procedure: Placebo Percutaneous Electrical Nerve Stimulation
Real Dry Needling (without PENS) + Placebo TENSActive comparatorParticipants will receive real ultrasound-guided dry needling as in Group 1 but without electrical stimulation. The needles will remain in place for 30 minutes, with the PENS channel disabled to act as placebo. Simultaneously, adhesive electrodes will be placed as in Group 1, with TENS channels disabled. Participants will be told the current is below the sensory threshold. The design of this intervention group aims to determine whether the therapeutic effects observed with the PENS technique are exclusively due to needle insertion (dry needling) or whether the passage of electrical current through the needle (as in Group 1) plays a decisive role in the outcomes obtained. To this end, real ultrasound-guided dry needling is applied at the same anatomical locations, but without activation of the electrical stimulation channel, the latter acting as a placebo. This comparison will allow the specific effect of electrical stimulation to be isolated within the context of the intervention.
Receives: Procedure: Placebo Transcutaneous Electrical Nerve Stimulation; Procedure: Real Dry Needling (without Percutaneous Electrical Nerve Stimulation)
Placebo PENS + Placebo TENSPlacebo comparatorParticipants will receive only sham interventions. Placebo PENS will be simulated with Streitberger needles (skin contact without penetration) and cable placement, and placebo TENS with adhesive electrodes connected to a disabled channel. Participants will be informed that current is below the sensory threshold. The procedure will last 30 minutes.
Receives: Procedure: Placebo Transcutaneous Electrical Nerve Stimulation; Procedure: Placebo Percutaneous Electrical Nerve Stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain intensity

    Pain intensity will be assessed using the NPRS, a single 11-point numerical rating scale widely validated across different patient populations, where 0 represents no pain and 10 represents the worst possible pain. Data obtained through the NPRS are easy to document, intuitively interpretable and meet regulatory requirements for pain assessment and documentation. The NPRS has been shown to be reliable in assessing LBP intensity, also predicting the degree of disability in these patients. A change of 2 points on the NPRS has been considered to reflect the MCID in patients with LBP, indicating that any change equal to or greater than this value can be considered clinically relevant. However, the MCID has not yet been established in patients with LBRLP and neuropathic characteristics; therefore, a variation of 2 points will be used as a reference value, as in patients with LBP and those with chronic pain in general.

    Measured: Baseline, immediately after the intervention and 1 week post-intervention.

Secondary outcomes (10)
  1. Disability

    Disability will be assessed using the Oswestry Disability Index (ODI), an instrument designed to evaluate the degree of disability associated with acute, subacute and chronic LBP. The ODI consists of a total of 10 items, one assessing pain and the remaining nine assessing activities of daily living, each rated on a 6-point ordinal scale ranging from the best to the worst scenario (0-5 points). The scores for each item will be summed to obtain a total between 0 and 50 points, with the following categories: no disability (0-4 points), mild disability (5-14 points), moderate disability (15-24 points), severe disability (25-34 points) and complete disability (35-50 points). The ODI has been shown to be reliable and valid for assessing disability in patients with LBP and has been validated in Spanish. The MCID varies across studies; in this case, the smallest reported value (a change of 5 points) will be used as the reference for significant changes.

    Measured: Baseline and 1 week post-intervention.

  2. Health-related quality of life

    The SF-12 questionnaire, a shortened version of the SF-36, will be used for this assessment. The SF-12 consists of 12 items that evaluate eight different parameters: physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems and mental health perception. The items are combined and transformed to provide both a physical and a mental health score, each ranging from 0 (worst) to 100 (best). The SF-12 has been shown to be valid and reliable in populations with chronic LBP. The MCID related to quality of life in patients with LBP has been established as improvements greater than 3.77 points in the mental component and 3.29 points in the physical component.

    Measured: Baseline and 1 week post-intervention.

  3. Neuropathic component of pain

    This variable will be measured using the S-LANSS pain scale, a self-administered instrument designed to identify patients with pain of neuropathic characteristics. It is a simple scale consisting of seven items with binary responses (yes or no), relating to the presence of symptoms (five items) or clinical signs (two items). The maximum possible score is 24 points, with scores equal to or greater than 12 considered clear indicators of the presence of a neuropathic pain component. The S-LANSS scale has been shown to be reliable for diagnosing pain with neuropathic characteristics and has been validated in Spanish.

    Measured: Baseline and 1 week post-intervention.

  4. Pressure pain threshold

    To assess PPT a pressure algometer will be used, determining the minimum amount of pressure required for the patient to feel pain. PPT will be measured at three different points on each side: tibial nerve (posterior aspect of the knee), peroneal nerve (at the level of the fibular head), and the sciatic nerve trunk (gluteal region), repeating each measurement three times and averaging the results. According to the classification by Shrout and Fleiss, algometry measurement of PPT at the tibial nerve has shown good intra-rater reliability (ICC = 0.64) and acceptable inter-rater reliability (ICC = 0.56) in asymptomatic individuals. For the peroneal nerve, intra-rater reliability is excellent (ICC = 0.84) and inter-rater reliability is good (ICC = 0.70). For the sciatic nerve, intra-rater reliability is excellent (ICC = 0.90) and inter-rater reliability is good (ICC = 0.75).

    Measured: Baseline, immediately after the intervention and 1 week post-intervention.

  5. SLR test outcome

    The test will be performed with the participant in a supine position, passively raising the lower limb by flexing the hip while keeping the knee extended. A recent meta-analysis has highlighted ongoing concerns regarding its reliability and diagnostic accuracy, suggesting that incorporating structural differentiation movements may improve its performance. Based on previous research of limited quality, the test has been reported to have high sensitivity and low specificity, although results vary between studies. Likelihood ratios also differ widely across investigations, with LR+ ranging from 1.07 to 4.73 and LR- from 0.27 to 0.96. It has been determined that diagnosing radicular pain and radiculopathy in patients with LBRLP, when based solely on history and physical examination, has only slight inter-rater reliability (Kappa 0.35). In terms of interpretation, the SLR test is considered positive when it elicits familiar symptoms that relieve upon returning to the starting position.

    Measured: Baseline, immediately after the intervention and 1 week post-intervention.

  6. Pain Descriptors: Familiar Symptomatology and Paresthesias

    Categorical scales will be used to record the extent to which the SLR test reproduces symptomatology recognized by the patient as familiar (not familiar, slightly familiar, considerably familiar or exact reproduction of symptoms) and the severity of any dysesthesias or paresthesias experienced (none, mild-moderate or severe). This questionnaire has demonstrated moderate to excellent inter-rater reliability (ICC = 0.78-0.96).

    Measured: Baseline, immediately after the intervention and 1 week post-intervention.

  7. Range of motion in hip flexion

    Data on the hip flexion ROM achieved during the SLR test will be collected. The participant will be in a supine position and the hip flexion movement will be recorded using anatomical reference points and assessed using Kinovea, a motion-analysis software. A previous study using this method reported excellent intra- and inter-rater reliability, with ICCs ranging from 0.985 to 0.999 and a minimal detectable change of 1.3-4° of hip flexion in patients with LBP. In contrast, a previous meta-analysis concluded that inter-rater reliability for ROM measurement during the SLR test is poor, with variations ranging from 13° to 20º.

    Measured: Baseline, immediately after the intervention and 1 week post-intervention.

  8. Sciatic nerve stiffness

    An experienced ultrasound researcher will perform shear wave elastography (SWE) to assess sciatic nerve stiffness using a Logiq P9 XDclear™ system with convex (1-6 MHz) and linear (6-15 MHz) probes. Exams will be bilateral in the subgluteal fossa, with participants prone, ankle neutral, and knee extended. The nerve will be identified axially for thickness, width and area, then imaged longitudinally for SWE. Stable transducer positioning will allow simultaneous B-mode and SWE display. Stiffness will be expressed in kPa, taking at least three measurements that will be averaged for analysis. All images will be acquired by the same investigator. This method shows good reliability (ICC = 0.869), and higher stiffness (≈11.3%) has been observed in affected legs of patients with LBRLP compared to their unaffected side and to healthy controls.

    Measured: Baseline, immediately after the intervention and 1 week post-intervention.

  9. Global perceived improvement

    Global perceived improvement will be measured using a 7-point Likert scale ranging from "much worse" to "much better." Clinical improvement will be considered in participants who report feeling "moderately better" or "much better".

    Measured: Immediately after the intervention and 1 week post-intervention.

  10. Adverse events

    Adverse events will be defined as any problem related to the intervention that causes symptoms lasting at least two days or requiring specific treatment.

    Measured: Through study completion, an average of 2 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jan 2026
  2. Study start13 May 2026
  3. Primary completionDec 2026 (estimated)
  4. Study completionNov 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
88 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07377357
Sponsor's protocol ID
25/504-E (IMM)
Status last verified
Nov 2025
First submitted
25 Nov 2025
Last updated
14 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Percutaneous Electrical Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation and Real Dry Needling (without Percutaneous Electrical Nerve Stimulation) in people with Sciatica, run by Universidad Complutense de Madrid at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain intensity (time frame: Baseline, immediately after the intervention and 1 week post-intervention.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in